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1. Introduction 
First identified in the late 1960s,
1
 and isolated in 1980,
2
 the 
rich chemistry of 1,3-diphenylbenzo[1,2,4]triazin-7-ones 1 
(Figure 1) has more recently been explored.
3-6
 Benzotriazinone 1a 
(R = H) and derivatives have been implicated as multi-target 
inhibitors in Alzheimer’s disease of beta-amyloid (Aβ) 
aggregation and acetyl-(AChE)/butyryl- (BChE) cholinesterase.
7
 
Scaffold 1 contains a highly conjugated iminoquinone motif and 
an iminoquinone derivative of  imidazo[5,4-f]benzimidazoles was 
shown to have good specificity (Pearson correlation coefficient of 
0.51) towards NAD(P)H:quinone oxidoreductase 1 (NQO1) 
expression using COMPARE analysis of toxicity towards the 60 
cell lines at the National Cancer Institute (NCI) Development 
Therapeutics Program (DTP).
8
  
We now report COMPARE analysis of the toxicity of 
benzotriazinones leading to the discovery of very strong 
correlations to pleurotin. The latter naturally occurring antibiotic 
is a para-quinone with a perhydroanthracene core, which was first 
isolated in the 1940s from the basidiomycete, Pleurotus griseus.
9
 
Though pleurotin has been synthesized,
10
 a multi-gram 
fermentation process using Hohenbuehelia atrocaerulea for 
supply of pleurotin to the NCI has been reported.
11
 Pleurotin 
possesses antibacterial,
9
 antifungal,
12
 and anti-cancer activity, 
including inhibiting the hypoxia-induced factor (HIF-1α), a 
transcription factor associated with many aspects of tumor 
growth.
13
 The underlying pathway to much of this biological  
activity is pleurotin’s ability to act as a potent inhibitor (IC50 
0.17 μM) of the thioredoxin (Trx)-thioredoxin reductase (TrxR) 
system.
14
  
Earlier reports more specifically describe pleurotin as an 
irreversible inhibitor of TrxR with a Ki of 0.28 μM.
13,15
 TrxR is a 
flavoprotein homodimer with each monomer containing a FAD 
prosthetic group, NADPH binding domain, and a redox-active 
selenothiol active site.
16,17 
TrxR is the only known enzyme to 
reduce Trx protein, which in turn provides reducing equivalents 
for a number of essential redox-dependent cellular processes, 
such as H2O2 metabolism, sulfate assimilation, and signal 
transduction.
18
 Trx protein is, however, over-expressed in a 
number of cancers, and is associated with increased cell 
proliferation, inhibition of apoptosis, and decreased patient 
survival.
19
 The reduced form of Trx protein inhibits the tumor 
suppressor protein PTEN (protein tyrosine phosphatase and tensin 
homolog).
20
 Therefore negative regulation of Trx protein through 
TrxR inhibition is a significant strategy for the discovery of new 
anti-cancer agents. Herein, we investigate the structural 
requirements of the 1,3-diphenylbenzo[1,2,4]triazin-7-ones 1a-1l, 
and the new compound 1-phenyl-3-(trifluoromethyl)benzo-
[1,2,4]triazin-7-one 2 for cytotoxicity against cancer cell lines, 
and inhibitory activity towards TrxR using a purified enzyme 
assay. 
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Figure 1.  Benzo[1,2,4]triazin-7-ones 1a-1l, 2 and pleurotin 
 
2. Results and discussion 
2.1. Synthesis 
The synthesis of 1,3-diphenylbenzo[1,2,4]triazin-7-ones 1a-1l 
was previously reported starting from 1,3-
diphenylbenzo[1,2,4]triazin-4-yl radical 3,
3-6
 and 1-phenyl-3-
(trifluoro-methyl)benzo[1,2,4]triazin-7-one 2 is similarly 
accessible by mild MnO2 oxidation of the analogous 
trifluoromethyl substituted radical 4 (Scheme 1).
4
 
 
 
 
 
 
 
Scheme 1. Synthesis of benzo[1,2,4]triazin-7-ones 
 
2.2. Development Therapeutic Program (DTP) National 
Cancer Institute (NCI) 60 human tumor cell line screen and 
COMPARE analysis 
NCI one dose (10 µM) mean graph data of parent 1,3-
diphenylbenzo[1,2,4]triazin-7-one 1a showed strong growth 
inhibition against a number of cancer cell lines, particularly 
leukemia, colon, melanoma and renal cancers (Figure 2). 
Significant activity was apparent towards the prostate cancer line 
DU-145 and breast cancer cell line MCF-7, and these cell lines 
were available to us at our laboratory in Galway. We investigated 
the toxicity profile of 1a, following selection of the compound for 
five-dose testing by the NCI, which established the GI50, LC50 and 
TGI. The stated parameters provide the seed vector through which 
the NCI COMPARE algorithm determines closely matching 
cytotoxicity profiles.
21
 Complete single and five dose data for 1a 
can be found in the supplementary data accompanying this article. 
COMPARE allows comparisons to be carried out towards all the 
synthetic compounds in the NCI database. The program applies 
the commercially available SAS statistical package to calculate a 
Pearson product-moment correlation coefficient (0 to ±1) to 
establish the degree of similarity between two cytotoxicity 
profiles. Coefficients in the range (±0.3 to ±0.5) are considered 
medium strength, while those above (±0.5) are considered strong. 
Out of ~70,000 compounds in the NCI database, pleurotin had 
one of the highest correlation coefficients to benzotriazinone 1a at 
0.84, which represents a very strong correlation (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Summary of DTP NCI-60 single dose (10 µM) 
screening results for benzotriazinones 1a and 2 expressed as 
average percent growth of each cancer cell type relative to 
untreated cells 
1-Phenyl-3-(trifluoromethyl)benzo[1,2,4]triazin-7-one 2 is 
structurally distinct from benzotriazinones 1a-1l since the 3-
phenyl is replaced by a strong inductively electron-withdrawing 
trifluoromethyl (CF3) group. Elevated toxicity towards the MCF-7 
cell line supported trends in our later obtained MTT assay data 
(Table 2). Compound 2 appeared overall somewhat less cytotoxic 
against the main cancer types in comparison to 1a (Figure 2), but 
with a very strong correlation to compound 1a and pleurotin using 
COMPARE analysis after the five dose testing (Table 1). The 
large pearson correlation coefficients (0.8) indicated possible 
common pathways for anti-cancer activity. 
Table 1.  Pearson correlation coefficients obtained by COMPARE 
analysis 
 
 
 
 
 
 
 
2.3. Cytotoxicity against normal and cancer cell lines using 
the MTT assay 
To determine the specificity and overall cytotoxicity towards 
selected cancer cell lines, the effect of substitution at the 6-
position of the 1,3-diphenylbenzo[1,2,4]triazin-7-one scaffold 
with amine, amide and alkoxy substituents was investigated 
(compounds 1a-1l in Figure 1). Cytotoxicity was determined 
against the prostate cancer cell line DU-145 and the breast cancer 
cell line MCF-7 using the MTT assay (Table 2). These cell lines 
form part of the NCI-60 human tumor cell line screen. As a 
control the response of a normal human-skin fibroblast cell line 
GM00637 was determined. 
Pleurotin displayed submicromolar toxicity towards all three cell 
lines investigated, with parent 1a showing comparable toxicity. 
Substitution with methoxy- and ethoxy-groups in compounds 1k 
and 1l and amide in 1j decreased toxicity to negligible values. 
The methoxy substituent (OMe) on heterocyclic quinones has 
been shown to lead to significant reductions in toxicity towards 
cell lines in comparison to its replacement with an aziridinyl 
substituent. The trends in toxicity correlate to a reduced electron-
affinity property as a result of the electron donation by the alkoxy 
substitutent.
22,23
 Cyclic amine substituents in 1f-1i led to a general 
reduction in toxicity values compared to the parent 1a, with the 
exception of pyrrolo-substituted benzotriazinone 1f. Compound 
Compound Pleurotin 2 
1a 0.842 0.803 
2 0.793 - 
1f showed the greatest specificity toward the MCF-7 cell line 
similar to the toxicity of pleurotin. Among the acyclic amines 1b-
1e, secondary amine substituents in 1c and 1d gave 
submicromolar toxicity. The ethylamino-substituent in 1d has a 
similar potency to the parent 1a with a comparative approximate 
two-fold reduction in toxicity towards the MCF-7 cell line. 1-
Phenyl-3-(trifluoromethyl)benzo[1,2,4]triazin-7-one 2 with a 
strong electron-withdrawing substituent at the 3-position was 
evaluated due to the lack of availability of benzotriazinones with 
electron-withdrawing substituents at the 6-position. Compound 2 
showed submicromolar toxicity towards the two cancer cell lines 
(DU-145 and MCF-7) with a 2- to 3-fold decrease in toxicity 
towards the normal skin fibroblast cell line (GM00637).
 
Table 2. Cytotoxicity evaluation using the MTT assay: IC50 values (µM)
a
 
 
2.4. Cyclic voltammetry  
Cyclic voltammetry on compounds 1a and 2 were carried out 
in anticipation that bioreductive activation may be implicated in 
cytotoxicity (Figure 3). Redox response experiments were carried 
out in dichloromethane, which showed that both 1a and 2 undergo 
two characteristic quasi-reversible one-electron redox processes 
corresponding to the 0/-1 redox transition (I and Iʹ) and -1/-2 
redox transition (II and IIʹ). Benzotriazinone 1a displayed a redox 
potential (E°ʹ) of -1.12 V vs. Fc/Fc
+
 for the 0/-1 redox transition 
(I) and -1.75 V vs. Fc/Fc
+
 for the -1/-2 redox transition (II). 
Benzotriazinone 2 produced a similar redox response to 1a, 
although E°ʹ values for equivalent redox couples (Iʹ and IIʹ) are 
shifted by approximately +0.23 V in the positive direction. This 
can be attributed to the strong inductive withdrawal by the 3-CF3 
of 2 relative to the 3-phenyl substituent present in 1a resulting in 
an enhanced susceptibility of 2 to undergo reduction. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cyclic voltammograms of 1a (blue line) and 2 (red line) 
recorded in dichloromethane (0.1 M TBAP) at a glassy carbon 
electrode (scan rate: 0.1 V s
-1
). Arrow indicates direction of scan 
Table 3. Formal Potentials (E°ʹ) (±0.010 V) calculated as (Epc + Epa)/2 from 
cyclic voltammograms recorded at 100 mVs-1 
 
2.5. Thioredoxin reductase (TrxR) inhibition assays 
To determine whether 1a and 2 inhibited TrxR, and to identify 
the mode of inhibition, enzyme activity was estimated in the 
absence or presence of varying concentrations of inhibitor. Data 
was analysed using the Lineweaver-Burk plot (Figure 4). In the 
case of 1a Vmax decreased and Km increased with increasing 
inhibitor, characteristic of mixed inhibition. However, 2 is more 
characteristic of uncompetitive inhibition where Vmax decreased 
with increasing inhibitor and Km was lower in the presence of 
inhibitor, than in the uninhibited condition. 
To estimate the Ki value, a secondary plot (Figure 5) of the 
slopes of the Lineweaver-Burk plot against inhibitor 
concentrations was generated. Ki values were found to be 3.90 
and 0.78 µM for compounds 1a and 2, respectively. The lower Ki 
for 2 towards the reductase enzyme may be attributed to it being 
more reducible than 1a as determined by cyclic voltammetry 
(Figure 3). Therefore benzotriazinones 1a and 2 clearly inhibit 
TrxR, but unlike pleurotin the mode of inhibition is reversible 
rather than irreversible. The Ki value for the electron-deficient 
iminoquinone 2 is closer in magnitude to that of pleurotin (Ki 0.28 
μM).
13,15
 
 
 
 
 
 
Compound E°ʹ [V] versus Fc/Fc+ 
 E°ʹ (I) E°ʹ (II) 
1a -1.12 -1.75 
2 -0.86 -1.55 
Compd R Cell Lines 
  
GM00637 DU-145 MCF-7 
Pleurotin 0.51 ± 0.12  
 
0.43 ± 0.06 0.28 ± 0.03 
1a H 0.23 ± 0.01 0.23 ± 0.03 0.81 ± 0.08 
1b NH2 2.04 ± 0.21 1.83 ± 0.08 0.95 ± 0.03 
1c NHMe 0.93 ± 0.03 0.98 ± 0.06 0.69 ± 0.12 
1d NHEt 0.24 ± 0.01 
 
 
0.22 ± 0.01 
 
 
1.62 ± 0.24 
1e NEt2 2.73 ± 0.36 3.11 ± 0.08  >5.0 
1f 
 
1.79 ± 0.12 2.46 ± 0.19 0.36 ± 0.08 
1g 
 
1.19 ± 0.02 0.61 ± 0.05 
 
 
1.98  ± 0.06 
1h 
 
2.29 ± 0.06 3.21 ± 0.37 
 
2.37 ± 0.07 
1i 
 
1.63 ± 0.31 
 
1.22 ± 0.06 0.97 ± 0.16 
1j 
 
>5.0 >5.0 >5.0 
1k OMe >5.0 
 
 
>5.0 
 
 
>5.0 
1l OEt >5.0 >5.0 >5.0 
2  1.61 ± 0.21 0.85 ± 0.04 0.60 ± 0.13 
a IC50
  represents the compound concentration required for the reduction 
of the mean cell viability to 50% of the control value after incubation for 
72 h at 37 oC 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Kinetics of thioredoxin reductase (TrxR) inhibition by 
1,3-diphenylbenzo[1,2,4]-triazin-7-one 1a and 1-phenyl-3-
(trifluoromethyl)benzo[1,2,4]triazin-7-one 2 using 5,5'-
dithiobis(2-nitrobenzoic) acid (DTNB) as the substrate: (a) 
Lineweaver-Burk plot with inhibitor 1a concentrations of 0 ( ), 
0.15 ( ), 0.30 ( ) and 0.50 ( ) µM. (b) Lineweaver-Burk 
plot with inhibitor 2 concentrations of 0 ( ), 0.30 ( ) and 1 ( ) 
µM 
 
 
 
 
 
 
 
 
 
 
Figure 5. Graphical determination of Ki for 1,3-
diphenylbenzo[1,2,4]triazin-7-one 1a and 1-phenyl-3-
(trifluoromethyl)benzo[1,2,4]triazin-7-one 2 using the slopes of 
the Lineweaver-Burk plots in Figure 4 versus inhibitor 
concentrations. 
3. Conclusions 
Using NCI COMPARE program, parent benzotriazinone 1a and 
3-CF3 substituted analogue 2 were found to have very strong 
correlations to a naturally occurring anti-cancer agent pleurotin. 
Benzotriazinones 1a and 2 are TrxR inhibitors, although the 
mechanism for inhibition is reversible rather than irreversible as 
for pleurotin. The latter may be attributed to differences in 
chemical structure with pleurotin containing an isolated non-
conjugated quinone motif.   
Varying the substituent at the 6-position of the 1,3-
diphenylbenzo[1,2,4]triazin-7-ones has a profound effect on 
toxicity. Benzotriazinone 1a is generally more cytotoxic towards 
cancer cell lines, although compound 2 shows greater specificity 
towards solid tumor cell lines in comparison to a normal 
fibroblast cell line. The latter CF3-substituted compound is more 
easily reducible and shows a more than five-fold greater 
inhibition of TrxR. Differences in the extent and type of TrxR 
inhibition as well as other cellular interactions may modulate the 
cytotoxicity of 1a and 2 towards normal and cancer cell lines. 
 
4. Experimental section 
4.1. Synthetic materials and methods 
4 .1 .1 .  General  
1,4-Dioxane was dried over CaH2. Reactions were protected 
from atmospheric moisture by CaCl2 drying tubes. All volatiles 
were removed under reduced pressure. All reaction mixtures and 
column eluents were monitored by TLC using commercial glass 
backed thin layer chromatography (TLC) plates (Merck Kieselgel 
60 F254). The plates were observed under UV light at 254 and 365 
nm. The technique of dry flash chromatography was used 
throughout for all non-TLC scale chromatographic separations 
using Merck Silica Gel 60 (less than 0.063 mm).
24
 Melting and 
decomposition points were determined using a TA Instruments 
DSC Q1000 with samples hermetically sealed in aluminium pans 
under an argon atmosphere using heating rates of 5 °C/min. IR 
spectra were recorded on a Shimadzu FTIR-NIR Prestige-21 
spectrometer with a Pike Miracle Ge ATR accessory and strong, 
medium and weak peaks are represented by s, m and w, 
respectively. 
1
H and 
13
C NMR spectra were recorded on a 
BrukerAvance 300 machine (at 300 and 75 MHz, respectively). 
Deuterated solvents were used for homonuclear lock and the 
signals are referenced to the deuterated solvent peaks. MALDI-
TOF MS were conducted on a Bruker BIFLEX III time-of-flight 
(TOF) mass spectrometer. 1,3-Diphenylbenzo[1,2,4]triazin-7-one 
(1a),
3
 6-amino-1,3-diphenylbenzo-[1,2,4]triazin-7-one (1b),
6
 6-
(methylamino)-1,3-diphenylbenzo[1,2,4]triazin-7-one (1c),
5
 6-
(ethylamino)-1,3-diphenylbenzo[1,2,4]triazin-7-one (1d),
6
 6-
(diethylamino)-1,3-diphenyl-benzo[1,2,4]triazin-7-one (1e),
7
 1,3-
diphenyl-6-(pyrrolidin-1-yl)benzo[1,2,4]triazin-7-one (1f),
7
 1,3-
diphenyl-6-(piperidin-1-yl)benzo[1,2,4]triazin-7-one (1g),
6
 6-
morpholino-1,3-diphenylbenzo[1,2,4]triazin-7-one (1h),
7
 1,3-
diphenyl-6-thiomorpholinobenzo[1,2,4]triazin-7-one (1i),
7
 N-(7-
oxo-1,3-diphenyl-1,7-dihydrobenzo[1,2,4]triazin-6-yl)acetamide 
(1j),
5
 6-methoxy-1,3-diphenylbenzo[1,2,4]triazin-7-one (1k),
7
 and 
6-ethoxy-1,3-diphenylbenzo-[1,2,4]triazin-7-one (1l)
6
 were 
synthesized according to literature procedures. 
4.1 .2 .  1-Phenyl-3 -
(tri f luoromethyl )benzo[1 ,2 ,4]triazin -7 -one  (2 )  
To a stirred solution of 1-phenyl-3(trifluoromethyl)-1,4-
dihydro-1,2,4-benzotriazin-4-yl (4)
4
 (44.2 mg, 0.16 mmol) in dry 
1,4-dioxane (4 mL) at ca. 20 °C was added MnO2 (0.696 g, 50 
equiv) and the reaction mixture stirred vigorously for 3 h. Upon 
completion, the reaction was poured onto a short silica pad and 
washed with n-hexane. Chromatography (n-hexane/diethyl ether, 
1:1) afforded the title compound 2 as dark purple shiny needles 
(43.3 mg, 93%); mp (DSC) onset: 140.5 °C, peak max: 144.9 °C 
(from n-hexane); Rf 0.58 (t-BuOMe); (found: C, 57.65; H, 2.67; 
N, 14.35. C14H8F3N3O requires C, 57.74; H, 2.77; N, 14.43%); 
λmax(DCM)/nm 281 (log ε 3.36), 291 inf (3.25), 481 inf (2.40), 
528 (2.56), 561 (2.48), 607 inf (2.12); νmax/cm
-1
 3061w (Ar C- H), 
1620m, 1605m, 1597m, 1549s (C=O), 1495m, 1466w, 1458w, 
1422w, 1400s, 1356s, 1333m, 1319w, 1304w, 1294w, 1246w, 
1217s, 1200s, 1177m, 1150s, 1136s, 1113m, 1096s, 1074w, 
1030w, 1001w, 984m, 926w, 908w, 853s, 824m, 775m, 733w; 
δH(300 MHz, CDCl3) 7.72 (1H, d, J 9.8 Hz), 7.67-7.58 (3H, m), 
7.56-7.48 (2H, m), 7.33 (1H, dd, J 9.8, 2.1 Hz), 6.12 (1H, d, J 1.9 
Hz); δC(75 MHz, CDCl3) 182.6 (s), 156.3 (s), 143.1 (d), 142.4 (q, 
2
JFC 39.0 Hz, CCF3), 139.9 (s), 136.6 (s), 132.2 (d), 130.8 (d), 
130.3 (d), 125.2 (d), 119.2 (q, 
1
JFC 273.6 Hz, CF3), 100.0 (d); 
MALDI-TOF (m/z): 293 (MH
+
+1, 4%), 292 (MH
+
, 100), 264 (7), 
257 (70), 239 (1), 209 (6), 196 (2), 172 (1), 133 (3). 
4.2. Cell culture and cytotoxicity evaluation 
4 .2 .1 .  Cel l  cul ture  
An SV40-transformed normal human fibroblast cell line 
(repository number GM00637) was obtained from the National 
Institute for General Medical Sciences (NIGMS) Human Genetic 
Cell Repository (Coriell Institute for Medical Research, New 
Jersey, USA). The DU-145 prostate cancer cell line (ATCC 
repository number HTB-81) was obtained from Prof. R.W.G. 
Watson, School of Medicine & Medical Sciences, University 
College Dublin, Ireland. The MCF-7 cell line, a human breast 
cancer cell line was obtained from Dr. Adrienne Gorman, 
Biochemistry, School of Natural Sciences, National University of 
Ireland Galway. 
The SV40-transformed normal human skin fibroblast cell line 
(GM00637) was grown in minimum essential media (MEM) 
Eagle-Earle BSS supplemented with 15% heat-inactivated fetal 
bovine serum (FBS), penicillin-streptomycin, 2 mM L-glutamine, 
2X essential and non-essential amino acids and vitamins. DU-145 
prostate cancer cells were grown in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 
penicillin-streptomycin and 2 mM L-glutamine. MCF-7 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing high glucose (4.5 mg/mL) and supplemented with 10% 
heat-inactivated FBS and 1% penicillin-streptomycin. 
4.2 .2 .   Cytotoxici ty  measurement  
Cell viability was determined using the MTT colorimetric 
assay.
25
 Normal cells were plated into 96-well plates at a density 
of 10,000 cells per well (200 µL per well) and allowed to adhere 
over a period of 24 h. DU-145 cells were plated into 96-well 
plates at a density of 2,000 cells per well (200 µL per well) and 
allowed to adhere over a period of 24 h. MCF-7 cells were plated 
into 96-well plates at a density of 1,000 cells per well (200 µL per 
well) and allowed to adhere over a period of 24 h. Compound 
solutions were applied in DMSO (1% v/v final concentration in 
well). Cells were then incubated at 37 °C under a humified 
atmosphere containing 5% CO2 for 72 h. Control cells were 
exposed to an equivalent concentration of DMSO alone. MTT (20 
µL, 5 mg/mL solution) was added, and the cells were incubated 
for another 4 h. The supernatant was removed carefully by 
pipette. The resultant MTT formazan crystals were dissolved in 
100 µL of DMSO and absorbance was determined on a plate 
reader at 550 nm with a reference at 690 nm. Cell viability is 
expressed as a percentage of the DMSO-only treated value. Dose 
response curves were analyzed by non-linear regression analysis 
and IC50 values were estimated using GraphPad Prism software, v 
6.03 (GraphPad Inc., San Diego, CA, USA). 
4.3. Electrochemistry 
Cyclic voltammograms were recorded using a PalmsSens 
EmStat3+ potentiostat. Samples (~2 mmol) were dissolved in 
dichloromethane containing 0.1 M tetrabutylammonium 
perchlorate (TBAP) as supporting electrolyte and 1 mM ferrocene 
(Fc) as an internal reference. Voltammograms were recorded in a 
single compartment electrochemical cell (0.5 mL volume) 
containing a glassy carbon disk working electrode (3 mm 
diameter), an Ag/AgCl reference electrode and a Pt wire counter 
electrode. All measurements were recorded under nitrogen at 
room temperature. 
4.4. Thioredoxin reductase (TrxR) inhibition studies 
4 .4 .1 .  Materials  
The thioredoxin reductase assay kit (Sigma Aldrich) contained 
all reagents and enzyme required for the thioredoxin reductase 
assay and was used as received. Rat liver thioredoxin reductase 
was in 50 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 300 
mM NaCl, and 10% glycerol. The working buffer contained 100 
mM potassium phosphate with 10 mM EDTA, 0.24 mM NADPH 
and the assay buffer 5× contained 500 mM potassium phosphate, 
pH 7.0 and 50 mM EDTA. 
4.4 .2 .  Enzyme kinetics   
The kinetics of rat liver thioredoxin reductase (TrxR) 
inhibition was analysed in 96-well microtiter plates. The 
experimental setup follows manufacturer’s instructions. The 
reduction of 5,5'-dithiobis(2-nitrobenzoic) acid (DTNB) with 
NADPH to 5-thio-2-nitro-benzoic acid (TNB) gave a linear 
increase in absorbance at 405 nm and 27 °C. Each assay point 
represents an average from three independent experiments carried 
out in duplicate. The absorbance was measured at intervals of 5 
minutes for a period of 50 minutes. Absorbance was measured 
using a Biotek Powerwave XS2 plate reader. Taking ΔA405 from 
the linear portion of the absorbance plot, TrxR activity was 
quantified using equation 1. 
 
 
Equation 1 
A unit of mammalian TrxR is the amount of enzyme that will 
cause an increase in A405 of 1.0 min
-1
mL
-1
 at pH 7.0 and 25 °C, 
where ΔA405 min
-1
(TrxR) = [ΔA405 min
-1
 (sample) - ΔA405 min
-1
 
(sample + inhibitor)]; dil = sample dilution factor; vol = total 
reaction volume; enzvol = enzyme volume. 
The enzyme specific activity (Units/µg protein) or initial 
velocity (V0) is calculated by dividing the UnitmL
-1
 by TrxR 
concentration (2.5 × 10
-3
 µg/mL) in the well. The double 
reciprocal Lineweaver-Burk is plotted using GraphPad Prism 
software, v 6.03 (GraphPad Inc., San Diego, CA, USA). The final 
concentration of DMSO in the assay did not exceed 3.2% (v/v). 
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